First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

• Breakthrough results in the treatment of a type of heart failure, which...
  Continue Reading >

Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the receipt of a decision by the Irish Tax Appeals......

Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress

• Delivered Year-over-Year Growth in Reported Revenue of +18.4% and Underlying...
  Continue Reading >

SBA holds Covid-19 vaccination drive

MUSCAT: To safeguard the health and safety of its employees and customers against the spread of Covid-19, Suhail Bahwan Automobiles (SBA) has initiated......

AstraZeneca says COVID-19 vaccine sales top $1bn -

British pharmaceuticals giant AstraZeneca said that its COVID-19 jab generated US$1.2bn in sales in the first half of the year as global vaccination......

Singer-Songwriter Charlie Marie Lyons and Dikembe Mutombo Foundation Ally to Support School Construction in Congo

Los Angeles, July 26, 2021 – The philanthropic work of NBA Global Ambassador Dikembe Mutombo is the inspiration for Los Angeles-based singer-songwriter......

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch......

IWBI Collaborates with Leading Organizations to Launch WELL Enterprise Provider Designation

The International WELL Building Institute (IWBI) today launched the WELL Enterprise Provider (WELL EP) designation for organizations that demonstrate......

Sultanate sees 55% fall in hepatitis patients

Patients with viral hepatitis decreased by 55 per cent to 133 in 2020 compared to 260 in 2019, according to the National Centre for Statistics and......

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA)......